title: Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
abstract: Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an increasingly important component of therapeutic regimens in oncology. The success of mAbs as a therapeutic class is a result of great strides that have been made in molecular biology and in biotechnology over the past several decades. Currently, there are 14 approved mAb products for oncology indications, and there are ten additional mAbs in late stages of clinical trials. Compared to traditional chemotherapeutic agents, mAbs have several advantages, including a long circulating half-life and high target specificity. Antibodies can serve as cytotoxic agents when administered alone, exerting a pharmacologic effect through several mechanisms involving the antigen binding (Fab) and/or Fc domains of the molecule, and mAbs may also be utilized as drug carriers, targeting a toxic payload to cancer cells. The extremely high affinity of mAbs for their targets, which is desirable with respect to pharmacodynamics (i.e., contributing to the high therapeutic selectivity of mAb), often leads to complex, non-linear, target-mediated pharmacokinetics. In this report, we summarize the pharmacokinetic and pharmacodynamics of mAbs that have been approved and of mAbs that are near approval for oncology indications, with particular focus on the molecular and cellular mechanisms responsible for their disposition and efficacy.
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA.
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Glassman
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA.
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Balthasar
keywords: Antibodies; monoclonal; oncology; pharmacodynamics; pharmacokinetics
references.citation: J Immunol. 2010 Jan 1;184(1):512-20
references.pmid: 19949082
references.citation: Nature. 1975 Aug 7;256(5517):495-7
references.pmid: 1172191
references.citation: Cancer Chemother Pharmacol. 2012 May;69(5):1229-40
references.pmid: 22271209
references.citation: Pharm Res. 2006 Jun;23(6):1275-84
references.pmid: 16715358
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Cancer Res. 1993 Sep 15;53(18):4322-8
references.pmid: 8364927
references.citation: Clin Cancer Res. 2010 Jan 15;16(2):699-710
references.pmid: 20068101
references.citation: Ann Pharmacother. 2011 Oct;45(10):1248-55
references.pmid: 21896924
references.citation: N Engl J Med. 2006 Sep 7;355(10):1018-28
references.pmid: 16908486
references.citation: Cancer. 2013 Aug 1;119(15):2728-36
references.pmid: 23633004
references.citation: Science. 1993 Jul 9;261(5118):212-5
references.pmid: 8327892
references.citation: N Engl J Med. 2008 Oct 23;359(17):1757-65
references.pmid: 18946061
references.citation: Cancer Sci. 2010 Aug;101(8):1840-5
references.pmid: 20491780
references.citation: Cancer Chemother Pharmacol. 2005 Oct;56(4):361-9
references.pmid: 15868146
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1749-55
references.pmid: 20194866
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: J Clin Oncol. 2010 Dec 10;28(35):5132-9
references.pmid: 21060033
references.citation: J Immunother. 2010 Jun;33(5):492-9
references.pmid: 20463598
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3918-28
references.pmid: 11579112
references.citation: Breast Cancer Res Treat. 2011 Jul;128(2):347-56
references.pmid: 20730488
references.citation: J Clin Oncol. 2012 May 20;30(15):1822-8
references.pmid: 22355053
references.citation: Blood. 2009 Apr 23;113(17):3891-5
references.pmid: 19182204
references.citation: J Nucl Med. 1990 Jul;31(7):1191-8
references.pmid: 2362198
references.citation: Blood. 2012 Apr 19;119(16):3698-704
references.pmid: 22389254
references.citation: Cancer Sci. 2012 May;103(5):933-8
references.pmid: 22335424
references.citation: Clin Pharmacokinet. 2012 Apr 1;51(4):247-60
references.pmid: 22420579
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: Eur J Immunol. 1997 Jan;27(1):239-47
references.pmid: 9022025
references.citation: N Engl J Med. 2010 Nov 4;363(19):1812-21
references.pmid: 21047225
references.citation: Blood. 2012 Jul 19;120(3):552-9
references.pmid: 22184404
references.citation: Oncogene. 2003 Oct 20;22(47):7359-68
references.pmid: 14576843
references.citation: J Clin Oncol. 2012 Jun 1;30(16):1953-9
references.pmid: 22547589
references.citation: J Pharmacol Exp Ther. 2002 Jan;300(1):346-53
references.pmid: 11752135
references.citation: Blood. 2002 Feb 1;99(3):754-8
references.pmid: 11806974
references.citation: Ann Oncol. 1998 Sep;9(9):995-1001
references.pmid: 9818074
references.citation: Blood. 1997 Sep 15;90(6):2188-95
references.pmid: 9310469
references.citation: Pharm Res. 2012 Sep;29(9):2354-66
references.pmid: 22740180
references.citation: Cancer Res. 1991 Aug 1;51(15):4052-8
references.pmid: 1855219
references.citation: Br J Clin Pharmacol. 2007 Sep;64(3):278-91
references.pmid: 17506867
references.citation: Gynecol Oncol. 2013 Jun;129(3):452-8
references.pmid: 23474348
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7
references.pmid: 12826605
references.citation: Drugs. 2011 May 28;71(8):1093-104
references.pmid: 21668044
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references.pmid: 16754935
references.citation: Clin Cancer Res. 2010 Mar 15;16(6):1915-23
references.pmid: 20197484
references.citation: Cancer Res. 1990 Feb 1;50(3 Suppl):814s-819s
references.pmid: 2404582
references.citation: MAbs. 2013 Jul-Aug;5(4):513-7
references.pmid: 23727858
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2190-6
references.pmid: 22614995
references.citation: Proc Natl Acad Sci U S A. 1983 Dec;80(23):7328-32
references.pmid: 6580648
references.citation: Angiogenesis. 2004;7(4):335-45
references.pmid: 15886877
references.citation: J Clin Oncol. 1999 Feb;17(2):478-84
references.pmid: 10080588
references.citation: AJNR Am J Neuroradiol. 2011 Apr;32(4):637-8
references.pmid: 21436340
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: J Clin Oncol. 2002 May 15;20(10):2453-63
references.pmid: 12011122
references.citation: Br J Haematol. 2010 Jul;150(1):58-71
references.pmid: 20408846
references.citation: Nat Rev Immunol. 2003 Dec;3(12):939-51
references.pmid: 14647476
references.citation: Cancer Res. 1992 Oct 1;52(19):5144-53
references.pmid: 1327501
references.citation: N Engl J Med. 2007 Jul 5;357(1):39-51
references.pmid: 17611206
references.citation: Ann Oncol. 2013 Feb;24(2):273-282
references.pmid: 22910839
references.citation: Mol Cancer. 2012 Jul 25;11:47
references.pmid: 22830443
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: J Exp Med. 1987 Nov 1;166(5):1351-61
references.pmid: 3500259
references.citation: Nat Prod Rep. 2013 May;30(5):625-39
references.pmid: 23525375
references.citation: Clin Pharmacol Ther. 1994 Sep;56(3):248-52
references.pmid: 7924119
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: Mol Cancer Ther. 2009 Sep;8(9):2616-24
references.pmid: 19723891
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: Oncogene. 2007 May 28;26(25):3644-53
references.pmid: 17530018
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2183-9
references.pmid: 22454421
references.citation: Clin Pharmacokinet. 2010 Nov;49(11):729-40
references.pmid: 20923247
references.citation: J Clin Pharmacol. 2013 Nov;53(11):1103-11
references.pmid: 23922054
references.citation: Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86
references.pmid: 18205003
references.citation: Science. 1983 Aug 26;221(4613):865-7
references.pmid: 6879183
references.citation: J Clin Oncol. 2011 Feb 1;29(4):398-405
references.pmid: 21172893
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5616-23
references.pmid: 17984186
references.citation: Clin Cancer Res. 2011 Nov 15;17(22):6958-62
references.pmid: 21900389
references.citation: Science. 1989 Jul 21;245(4915):301-5
references.pmid: 2787530
references.citation: BMC Cancer. 2010 Jun 03;10:255
references.pmid: 20525277
references.citation: Cancer Biol Ther. 2007 Feb;6(2):145-50
references.pmid: 17218777
references.citation: Prog Allergy. 1969;13:1-110
references.pmid: 4186070
references.citation: Clin Pharmacol Ther. 2008 Nov;84(5):548-58
references.pmid: 18784655
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4116-23
references.pmid: 19636016
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: Blood. 2004 May 1;103(9):3278-81
references.pmid: 14726385
references.citation: J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32
references.pmid: 11999290
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6517-22
references.pmid: 17065274